Citius Q3 net loss $8.5M; FDA CRL for LYMPHIR (no safety/efficacy issues); $33.3M cash runway to Aug 2024

Citius Pharmaceuticals, Inc.

2023-Q3 EPS reported -$0.15

Net loss of $8.5M ($0.06 EPS) for Q3 2023; nine-month loss $22.6M ($0.15 EPS).
Cash $33.3M, runway through Aug 2024; $13.8M net from May 2023 $1.20/share offering.
Mino-Lok Phase 3 trial achieved 92 required events (pending confirmation); Halo-Lido Phase 2b topline positive.
LYMPHIR received FDA CRL on July 28; no clinical safety/efficacy issues; planning resubmission.
R&D expenses $3.8M (down from $4.9M); G&A $3.7M (up from $3.0M) due to pre-launch activities.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Citius Pharmaceuticals, Inc. reported the fiscal third quarter ended June 30, 2023 results: net income Net loss was $8.5 million, or ($0.06) per share for the three months ended June 30, 2023.

Period: the fiscal third quarter ended June 30, 2023
Net income: Net loss was $8.5 million, or ($0.06) per share for the three months ended June 30, 2023
Result: reported results

Exact text from the filing

Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2023 Financial Results and Provides Business Update

View on SEC.gov

Browse all earnings releases →

Citius Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-23-067474

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.